AU2013320313B2 - Outer membrane vesicles - Google Patents

Outer membrane vesicles Download PDF

Info

Publication number
AU2013320313B2
AU2013320313B2 AU2013320313A AU2013320313A AU2013320313B2 AU 2013320313 B2 AU2013320313 B2 AU 2013320313B2 AU 2013320313 A AU2013320313 A AU 2013320313A AU 2013320313 A AU2013320313 A AU 2013320313A AU 2013320313 B2 AU2013320313 B2 AU 2013320313B2
Authority
AU
Australia
Prior art keywords
ala
lys
thr
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013320313A
Other languages
English (en)
Other versions
AU2013320313A1 (en
Inventor
Emiliano Chiarot
Guido Grandi
Immaculada Margarit Y Ros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2013320313A1 publication Critical patent/AU2013320313A1/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA Request for Assignment Assignors: NOVARTIS AG
Application granted granted Critical
Publication of AU2013320313B2 publication Critical patent/AU2013320313B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2013320313A 2012-09-18 2013-09-18 Outer membrane vesicles Ceased AU2013320313B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261702296P 2012-09-18 2012-09-18
US61/702,296 2012-09-18
US201361799311P 2013-03-15 2013-03-15
US61/799,311 2013-03-15
PCT/EP2013/069415 WO2014044728A1 (en) 2012-09-18 2013-09-18 Outer membrane vesicles

Publications (2)

Publication Number Publication Date
AU2013320313A1 AU2013320313A1 (en) 2015-02-26
AU2013320313B2 true AU2013320313B2 (en) 2018-07-12

Family

ID=49237191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013320313A Ceased AU2013320313B2 (en) 2012-09-18 2013-09-18 Outer membrane vesicles

Country Status (9)

Country Link
US (1) US9764027B2 (https=)
EP (3) EP2897635A1 (https=)
JP (1) JP6283674B2 (https=)
CN (1) CN104602702B (https=)
AU (1) AU2013320313B2 (https=)
CA (1) CA2882382A1 (https=)
MX (1) MX363529B (https=)
RU (1) RU2662970C2 (https=)
WO (1) WO2014044728A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5814507B2 (ja) * 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
WO2015155178A1 (en) * 2014-04-07 2015-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for producing outer membrane vesicles
BE1022553A1 (fr) * 2014-05-07 2016-05-31 Glaxosmithkline Biologicals Sa Mutants de spy0269
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
MX2017015404A (es) 2015-06-02 2018-05-22 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
CN105861402B (zh) * 2015-07-20 2020-02-14 中国医学科学院医学生物学研究所 将异源蛋白呈递于大肠杆菌外膜囊泡表面的新型疫苗形式
CN106866804B (zh) * 2015-12-11 2021-03-05 中国科学院植物研究所 一种与植物光合作用相关的cam01蛋白及其编码基因和应用
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
GB201607510D0 (en) * 2016-04-29 2016-06-15 Inst Of Food Res The Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (OMV) for delivery to the GI-tract
US12109259B2 (en) * 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
SI3544637T1 (sl) * 2016-11-25 2021-02-26 Glaxosmithkline Biologicals S.A. Nativni OMV-antigen konjugati in njihova uporaba
BR112019019440A2 (pt) 2017-03-31 2020-04-14 Indian Council Medical Res vacina contra febre tifoide a base de vesículas de membrana externa de duas cepas diferentes de espécies de salmonella tifoide
CA3063419A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
GB201708277D0 (en) * 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
US11123415B2 (en) * 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
CA3096849A1 (en) * 2018-04-10 2019-10-17 The Administrators Of The Tulane Educational Fund Burkholderia pseudomallei complex outer membrane vesicles as adjuvants
CN109554311B (zh) * 2018-12-18 2022-01-14 中国农业科学院兰州兽医研究所 一种鼠伤寒沙门氏菌外膜囊泡的提取方法
CN113727722A (zh) * 2019-02-22 2021-11-30 伊夫罗生物科学公司 细菌膜制剂
EP3960191A4 (en) * 2019-04-26 2023-01-04 MD Healthcare Inc. PROTEIN DERIVED FROM STREPTOCOCCUS PYOGENES BACTERIA AND ITS USE
CN110272910A (zh) * 2019-06-25 2019-09-24 四川农业大学 一种包括jev抗原基因的重组载体、重组菌株和递呈jev抗原的外膜囊泡及其应用
US20220378902A1 (en) * 2019-08-22 2022-12-01 Sichuan University Bacterial membrane vesicles, and separation and preparation system and method therefor
EP4090773A2 (en) 2020-01-17 2022-11-23 Université catholique de Louvain Genetically modified bacterium with altered envelop integrity and uses thereof
CA3168201A1 (en) * 2020-02-18 2021-08-26 Vaxcyte, Inc. Group a strep immunogenic compositions with polysaccharide-protein conjugates
WO2022026896A2 (en) * 2020-07-30 2022-02-03 Omvax, Inc. Sars-cov-2 receptor binding domain in native outer membrane vesicles
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用
CN119932075A (zh) * 2025-01-25 2025-05-06 四川大学 一种携带外源蛋白的重组单增李斯特菌膜囊泡及其制备方法和应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE173634T1 (de) 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2297072A1 (en) 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999061053A1 (en) 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン エセ.ピー.アー. Chlamydiapneumoniaeに対する免疫化
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003018054A1 (en) 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
RU2364418C2 (ru) * 2002-08-02 2009-08-20 ГлаксоСмитКлайн Байолоджикалз с.а. ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
EP1871888A4 (en) 2005-03-30 2013-08-21 Novartis Vaccines & Diagnostic HAEMOPHILUS INFLUENZAE OF TYPE B
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
RU2007146137A (ru) 2005-05-12 2009-06-27 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Иммуногенные композиции на основе chlamydia trachomatis
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP1954306A2 (en) 2005-10-25 2008-08-13 Novartis Vaccines and Diagnostics S.r.l. Compositions comprising yersinia pestis antigens
EP2292644A3 (en) * 2006-07-07 2011-05-25 Intercell AG Small Streptococcus pyogenes antigens and their use
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0717187D0 (en) 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
WO2009109860A2 (en) 2008-03-06 2009-09-11 Novartis Ag Mutant forms of chlamydia htra
UA99659C2 (uk) 2008-05-30 2012-09-10 Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
KR101042541B1 (ko) 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 g(-) 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
NZ591633A (en) * 2008-09-17 2012-10-26 Novartis Ag Combination gas vaccines and therapeutics
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
AU2011288203A1 (en) * 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
GB201009861D0 (en) * 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERLANDA SCORZA FRANCESCO ET AL, MOLECULAR & CELLULAR PROTEOMICS : MCP MAR 2008, (200803), vol. 7, no. 3, ISSN 1535-9484, pages 473 - 485 *
D. J. CHEN ET AL, "Delivery of foreign antigens by engineered outer membrane vesicle vaccines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20100216), vol. 107, no. 7, doi:10.1073/pnas.0805532107, ISSN 0027-8424, pages 3099 - 3104 *
DONG CHAN MOON ET AL,, THE JOURNAL OF MICROBIOLOGY, THE MICROBIOLOGICAL SOCIETY OF KOREA, HEIDELBERG, (20120227), vol. 50, no. 1, doi:10.1007/S12275-012-1589-4, ISSN 1976-3794, pages 155 - 160 *
KESTY et al, J Biol Chem (2004), 279: 2069-2076 *
MURALINATH MANEESHA ET AL, INFECTION AND IMMUNITY FEB 2011, (201102), vol. 79, no. 2, ISSN 1098-5522, pages 887 - 894 *

Also Published As

Publication number Publication date
EP4056198A3 (en) 2022-12-07
RU2662970C2 (ru) 2018-07-31
CN104602702A (zh) 2015-05-06
US20150231232A1 (en) 2015-08-20
CN104602702B (zh) 2021-08-27
JP2015535812A (ja) 2015-12-17
CA2882382A1 (en) 2014-03-27
EP2897635A1 (en) 2015-07-29
EP3400960A1 (en) 2018-11-14
EP4056198A2 (en) 2022-09-14
MX2015002484A (es) 2015-06-05
JP6283674B2 (ja) 2018-02-21
MX363529B (es) 2019-03-27
US9764027B2 (en) 2017-09-19
WO2014044728A1 (en) 2014-03-27
AU2013320313A1 (en) 2015-02-26
RU2015106917A (ru) 2016-11-10

Similar Documents

Publication Publication Date Title
AU2013320313B2 (en) Outer membrane vesicles
CN102906245B (zh) 高起泡性志贺氏菌菌株
US12054521B2 (en) FhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof
US20110300171A1 (en) Factor h binding protein immunogens
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
JP2011512152A (ja) 改善された溶解度を有するEscherichiacoli免疫原
AU2010309405B2 (en) Diagnostic and therapeutic methods for rheumatic heart disease based upon group a Streptococcus markers
EP2890394A1 (en) Stabilised proteins for immunising against staphylococcus aureus
EP2890387A1 (en) Stabilised proteins for immunising against staphylococcus aureus
US20180256701A1 (en) Pseudomonas antigens and antigen combinations
HK40074942A (en) Outer membrane vesicles
US20130017214A1 (en) Bacteremia-associated antigen from staphylococcus aureus
BR112012006912B1 (pt) Hipervesiculação de cepas de shigella

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA

Free format text: FORMER APPLICANT(S): NOVARTIS AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired